Letter by McCaw et al Regarding Article, “The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease”
- 5 January 2021
- journal article
- letter
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 143 (1), E1-E2
- https://doi.org/10.1161/circulationaha.120.050723
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- The COMPASS TrialCirculation, 2020
- Using the Restricted Mean Survival Time Difference as an Alternative to the Hazard Ratio for Analyzing Clinical Cardiovascular StudiesCirculation, 2019
- Restricted Mean Survival Time as a Measure to Interpret Clinical Trial ResultsJAMA Cardiology, 2017
- Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority StudiesAnnals of Internal Medicine, 2015